← Back to headlines
J&J's Rybrevant Faspro Granted FDA Priority Review for Head and Neck Cancer
Johnson & Johnson has received FDA priority review for its Rybrevant Faspro treatment, specifically for use in head and neck cancer, potentially accelerating its availability.
30 Jul, 13:10 — 30 Jul, 13:10
Sources
Showing 1 of 1 sources
Related Stories
Wall Street Futures Steady as Investors Await Nvidia Results and Fed Signals
28m ago
Meta to Launch Hatch AI Agent Platform in Coming Weeks
37m ago
Hanwha Aerospace Establishes US Unit for Global LNG Business Expansion
44m ago
Big Food Industry Fights India's Proposed 'Red Flag' Labels on Sugary Drinks and Chips
50m ago